Research Article

An Oral Formulation of the Probiotic, Bacillus subtilis HU58, Was Safe and Well Tolerated in a Pilot Study of Patients with Hepatic Encephalopathy

Figure 3

Changes in blood ammonia levels (a) by treatment group and (b) for patients stratified by baseline blood ammonia level; placebo group: n = 10, probiotic group: n = 28 (ammonia data were missing for 1 patient in each group); ns = not significant;∗ ∗p ≤ 0.01.